Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders.

Q3 Medicine
Personality Neuroscience Pub Date : 2020-03-19 eCollection Date: 2020-01-01 DOI:10.1017/pen.2020.2
N McNaughton, P Glue
{"title":"Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders.","authors":"N McNaughton,&nbsp;P Glue","doi":"10.1017/pen.2020.2","DOIUrl":null,"url":null,"abstract":"<p><p>Psychiatric disorders can often be viewed as extremes of personality traits. The primary action of drugs that ameliorate these disorders may, thus, be to alter the patient's position on a relevant trait dimension. Here, we suggest that interactions between such trait dimensions may also be important for disorder. Internalizing disorders show important differences in terms of range of activity and speed of response of medications. Established antidepressant and anxiolytic medications are slow in onset and have differing effects across different internalizing disorders. In contrast, low-dose ketamine is rapidly effective and improves symptom ratings in all internalizing disorders. To account for this, we propose a \"double hit\" model for internalizing disorders: generation (and maintenance) require two distinct forms of neural dysfunction to coincide. One hit, sensitive to ketamine, is disorder-general: dysfunction of a neural system linked to high levels of the personality trait of neuroticism. The other hit is disorder-specific: dysfunction of one of a set of disorder-specific neural modules, each with its own particular pattern of sensitivity to conventional drugs. Our hypothesis applies only to internalizing disorders. So, we predict that ketamine will be effective in simple phobia and (perhaps partially) in anorexia nervosa, but would make no such prediction about other disorders where neuroticism might also be important secondarily (e.g. attention deficit hyperactivity disorder and schizophrenia).</p>","PeriodicalId":36424,"journal":{"name":"Personality Neuroscience","volume":" ","pages":"e2"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/pen.2020.2","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personality Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/pen.2020.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 9

Abstract

Psychiatric disorders can often be viewed as extremes of personality traits. The primary action of drugs that ameliorate these disorders may, thus, be to alter the patient's position on a relevant trait dimension. Here, we suggest that interactions between such trait dimensions may also be important for disorder. Internalizing disorders show important differences in terms of range of activity and speed of response of medications. Established antidepressant and anxiolytic medications are slow in onset and have differing effects across different internalizing disorders. In contrast, low-dose ketamine is rapidly effective and improves symptom ratings in all internalizing disorders. To account for this, we propose a "double hit" model for internalizing disorders: generation (and maintenance) require two distinct forms of neural dysfunction to coincide. One hit, sensitive to ketamine, is disorder-general: dysfunction of a neural system linked to high levels of the personality trait of neuroticism. The other hit is disorder-specific: dysfunction of one of a set of disorder-specific neural modules, each with its own particular pattern of sensitivity to conventional drugs. Our hypothesis applies only to internalizing disorders. So, we predict that ketamine will be effective in simple phobia and (perhaps partially) in anorexia nervosa, but would make no such prediction about other disorders where neuroticism might also be important secondarily (e.g. attention deficit hyperactivity disorder and schizophrenia).

Abstract Image

Abstract Image

氯胺酮与神经质:内化障碍的双重打击假说。
精神障碍通常被视为人格特征的极端。因此,改善这些疾病的药物的主要作用可能是改变患者在相关特征维度上的位置。在这里,我们认为这些特征维度之间的相互作用可能对障碍也很重要。内化障碍在药物的活动范围和反应速度方面表现出重要的差异。现有的抗抑郁和抗焦虑药物起效缓慢,对不同的内化障碍有不同的效果。相比之下,低剂量氯胺酮在所有内化障碍中迅速有效并改善症状评分。为了解释这一点,我们提出了一种内化障碍的“双重打击”模型:产生(和维持)需要两种不同形式的神经功能障碍同时发生。一种对氯胺酮敏感的疾病是全身性紊乱:神经系统功能障碍与高度神经质的人格特征有关。另一个打击是疾病特异性:一组疾病特异性神经模块中的一个功能障碍,每个模块都有自己对常规药物的特定敏感模式。我们的假设只适用于内化障碍。因此,我们预测氯胺酮将对单纯的恐惧症和(可能部分)神经性厌食症有效,但对其他神经过敏也可能是次要的疾病(如注意缺陷多动障碍和精神分裂症)没有这样的预测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Personality Neuroscience
Personality Neuroscience Medicine-Neurology (clinical)
CiteScore
2.90
自引率
0.00%
发文量
4
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信